Autolus Therapeutics PLC Sponsored ADR

AUTL Healthcare Biotechnology

In the quarter to June 2026, revenue grew 118.4%, EPS grew 16.7% and free cash flow grew 67.6%, each against the same quarter a year earlier.

1.60 0.14 −8.05%
Market cap
$463.1M
P/E
0.0×
Fwd P/E
−1.7×
Dividend yield
—
F-score
3/9
Altman Z
−3.17
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

— 2 3 —
ROE
(60.56%) (94.98%) (120.42%) (133.00%)
ROA
(30.19%) (41.92%) (45.38%) (46.15%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(45.11%) (67.49%) (78.71%) (85.46%)
Average Days of Receivables
232.76 116.32 109.01 138.03
Free Cash Flow per Share
(1.15) (1.22) (1.08) (0.87)
Free Cash Flow
(306.77) (323.77) (286.81) (232.73)
Other line items

Show all line items

Columns are period end dates · fundamentals updated 28 Sep 2026